Distinguished in Rheumatoid Arthritis (RA)

Dr. Sheerin Javed

Rheumatology
537 Stanton Christiana Rd, Suite 212, 
Newark, DE 
Accepting New Patients
Offers Telehealth
Distinguished in Rheumatoid Arthritis (RA)
537 Stanton Christiana Rd, Suite 212, 
Newark, DE 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Sheerin Javed is a Rheumatologist in Newark, Delaware. Dr. Javed is rated as a Distinguished provider by MediFind in the treatment of Rheumatoid Arthritis (RA). Her top areas of expertise are Rheumatoid Arthritis (RA), Psoriatic Arthritis, Dermatomyositis, and Osteoporosis. Dr. Javed is currently accepting new patients.

Her clinical research consists of participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has participated in 5 clinical trials in the study of Rheumatoid Arthritis (RA).

Specialties
Rheumatology
Licenses
Internal Medicine in DE
Hospital Affiliations
Christiana Hospital
Union Hospital Of Cecil County
Languages Spoken
English
Russian
Sindhi
Spanish
Urdu
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 11 Less Insurance Carriers -

Locations

537 Stanton Christiana Rd, Suite 212, Newark, DE 19713

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A 52-week, Phase 3, Multicentre, Randomised, Double Blind, Efficacy and Safety Study Comparing GSK3196165 With Placebo and With Tofacitinib, in Combination With Methotrexate in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate
A 52-week, Phase 3, Multicentre, Randomised, Double Blind, Efficacy and Safety Study Comparing GSK3196165 With Placebo and With Tofacitinib, in Combination With Methotrexate in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate
Enrollment Status: Completed
Publish Date: March 27, 2024
Intervention Type: Biological, Drug
Study Drugs: GSK3196165, Tofacitinib, Methotrexate, Folic acid
Study Phase: Phase 3
A Multicenter, Open-Label, Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis
A Multicenter, Open-Label, Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis
Enrollment Status: Completed
Publish Date: October 12, 2023
Intervention Type: Drug
Study Drugs: Olokizumab, Methotrexate
Study Phase: Phase 3
A Randomized, Double-Blind, Parallel-Group, Placebo- and Active-Controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate Therapy
A Randomized, Double-Blind, Parallel-Group, Placebo- and Active-Controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate Therapy
Enrollment Status: Completed
Publish Date: September 21, 2023
Intervention Type: Drug
Study Phase: Phase 3
A Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Tumor Necrosis Factor Alpha (TNF-α) Inhibitor Therapy
A Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Tumor Necrosis Factor Alpha (TNF-α) Inhibitor Therapy
Enrollment Status: Completed
Publish Date: September 21, 2023
Intervention Type: Drug
Study Drug: Olokizumab
Study Phase: Phase 3
A 24-week, Phase 3, Multicentre, Randomised, Double-blind, Efficacy and Safety Study, Comparing GSK3196165 With Placebo and With Sarilumab, in Combination With Conventional Synthetic DMARDs, in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biological DMARDs and/or Janus Kinase Inhibitors
A 24-week, Phase 3, Multicentre, Randomised, Double-blind, Efficacy and Safety Study, Comparing GSK3196165 With Placebo and With Sarilumab, in Combination With Conventional Synthetic DMARDs, in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biological DMARDs and/or Janus Kinase Inhibitors
Enrollment Status: Completed
Publish Date: July 17, 2023
Intervention Type: Drug, Biological
Study Drugs: GSK3196165, Sarilumab, csDMARDs
Study Phase: Phase 3
View 4 Less Clinical Trials
Similar Doctors
Elite in Rheumatoid Arthritis (RA)
Dr. Joshua F. Baker
Rheumatology
Elite in Rheumatoid Arthritis (RA)
Dr. Joshua F. Baker
Rheumatology

Penn Rheumatology Perelman

3400 Civic Center Boulevard, South Pavilion, 1st Floor, 
Philadelphia, PA 
 (29.8 miles away)
215-662-2454
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Joshua Baker is a Rheumatologist in Philadelphia, Pennsylvania. Dr. Baker is rated as a Distinguished provider by MediFind in the treatment of Rheumatoid Arthritis (RA). His top areas of expertise are Rheumatoid Arthritis (RA), Arthritis, Rheumatoid Lung Disease, Knee Replacement, and Aortic Valve Replacement. Dr. Baker is currently accepting new patients.

Elite in Rheumatoid Arthritis (RA)
Dr. Martin J. Bergman
Rheumatology
Elite in Rheumatoid Arthritis (RA)
Dr. Martin J. Bergman
Rheumatology
23 W Chester Pike Ste 201, 
Ridley Park, PA 
 (21.3 miles away)
610-521-1701
Languages Spoken:
English
See accepted insurances

Martin Bergman is a Rheumatologist in Ridley Park, Pennsylvania. Dr. Bergman is rated as a Distinguished provider by MediFind in the treatment of Rheumatoid Arthritis (RA). His top areas of expertise are Rheumatoid Arthritis (RA), Arthritis, Psoriatic Arthritis, and Psoriasis.

Distinguished in Rheumatoid Arthritis (RA)
Dr. Elizabeth C. Hsia
Rheumatology
Distinguished in Rheumatoid Arthritis (RA)
Dr. Elizabeth C. Hsia
Rheumatology

Penn Rheumatology Perelman

3400 Civic Center Boulevard, South Pavilion, 1st Floor, 
Philadelphia, PA 
 (29.8 miles away)
215-662-2454
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Elizabeth Hsia is a Rheumatologist in Philadelphia, Pennsylvania. Dr. Hsia is rated as a Distinguished provider by MediFind in the treatment of Rheumatoid Arthritis (RA). Her top areas of expertise are Psoriatic Arthritis, Arthritis, Psoriasis, and Ankylosing Spondylitis. Dr. Hsia is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Javed's expertise for a condition
ConditionClose
      View All 13 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile